Salvador Borges-Neto
Salvador Borges-Neto

Salvador Borges-Neto

Professor of Radiology



1. Diagnostic and Prognostic Utility of Cardiovascular Nuclear Medicine in  Heart Disease.
2. The Role of Cardiac PET/CT  in Cardiac Sarcoidosis and Ischemic Heart Disease.
3. The Role of Nuclear Cardiology in Diagnosis and Management of Amyloidosis.
4. Left Ventricular Dyssynchrony Evaluation by GSPECT.

I am a Professor of Radiology (Nuclear Medicine) and Internal Medicine at Duke University Medical Center. I also serve as the Medical Director of Nuclear Cardiology at Duke Health System with Duke Heart Center. I received my medical doctorate from the Federal Fluminense University in Brazil. I subsequently completed a Cardiology Fellowship at Antonio Pedro University Hospital in Brazil and a second Fellowship in the Medicine/Cardiovascular division at Brigham and Women's Hospital in Boston. I continued my education with a fellowship in Nuclear Cardiology at the Methodist Hospital Baylor College of Medicine in Houston, Texas and finally in Nuclear Medicine in the Department of Radiology at Duke University Medical Center. I have lectured extensively internationally and have published 130+ publications in peer reviewed scientific professional journals. I am a founding member of the American Society of Nuclear Cardiology, Fellow of the American College of Cardiology, Fellow of the American College of Nuclear Medicine and Fellow of the American Heart Association. My clinical and Research interests include the role of cardiac imaging in predicting outcomes and guiding therapy. I have developed one of the largest Nuclear Cardiology Data Bases in the US. More recently my primarily research interest also includes the use of New Radiopharmaceuticals for the Diagnosis and Treatment of Oncologic Diseases (Theranostics). I have led a Team for the implementation of Diagnosis and Treatment of Neuroendocrine Tumors which became a Center of Reference for this Disease Diagnosis and Treatment with PRRT. serving as the PI for Expanded Access for Therapeutic Use of 177-Lu-DOTAO-Tyr3-Octreotide (Advanced Accelerator Applications SA – AAA) –Compationate Use – “177 Lu-Dotatate for Midgut Neuroendocrine Tumors and 177 Lu-Dotatate for GPENET’. Clinical Trials.Gov. 


Professor of Radiology in the School of Medicine

2008 School of Medicine

Professor of Medicine in the School of Medicine

2008 School of Medicine

Member of the Duke Cancer Institute in the School of Medicine

2018 School of Medicine


M.D. 1981

1981 Federal University of Fluminense (Brazil)

Intern in Medicine

1982 Federal University of Fluminense (Brazil)

Clinical Fellowship

1984 Federal University of Fluminense (Brazil)

Research Fellowship

1985 Harvard University

Research Fellowship

1986 Baylor, College of Medicine

Research Fellowship

1991 Duke University, School of Medicine

Nuclear Medicine Residency

1993 Duke University, School of Medicine

Publications, Grants & Awards

Offices & Contact

Trent Drive - Duke Circle - Duke Medical Pavillion
Durham, NC
Box 3949 Med Ctr
Durham, NC